Use this URL to cite or link to this record in EThOS:
Title: Examining the consequence of targeting mircotubules in prostate cancer
Author: Stockley, Jacqueline
ISNI:       0000 0004 2669 1073
Awarding Body: University of Newcastle Upon Tyne
Current Institution: University of Newcastle upon Tyne
Date of Award: 2008
Availability of Full Text:
Access from EThOS:
Prostate Cancer is the most commonly diagnosed cancer in males in the UK. Whilst localised disease can be treated by surgery or radiotherapy (Labrie, 2007; Walsh, 2002) patients presenting with clinically apparent prostate cancer often have metastatic disease. Androgen ablation is the first line treatment for metastatic prostate cancer however, although the disease initially responds to androgen withdrawal almost all patients relapse after a median period of approximately 2 years and become castrate resistant (Tomioka et al., 2007). Docetaxel is currently the only drug which has been found to extend survival in these patients (Petrylak et al., 2004; Tannock et al., 2004). With the development of life extending microtubule targeting agents, including Docetaxel (Di Lorenzo et al., 2007) it has become necessary to investigate the effect of androgen ablation on the new regimens. In this study the consequence of targeting the microtubules with Docetaxel in prostate cancer is investigated, including how this interacts with current therapeutic regimes.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID:  DOI: Not available